Experimental Treatment for Psoriasis
common.study.values.description
“A Safety Study of LY3462817 in Participants With Psoriasis”
This study is being conducted to determine how safe and how well tolerated LY3462817 is when given to participants with psoriasis. Blood tests will be done to check how much LY3462817 is in the bloodstream and how long the body takes to get rid of it. The study will last up to one year and one month for each participant.
common.study.values.location
participant.ui.study.affiliations-map.online-study.header-virtual
participant.ui.study.affiliations-map.online-study.text
common.study.values.methods
common.study.methods.has-drugs-yes
common.study.methods.is-healthy-yes
Drug - LY3462817 - IV
Administered IV
Drug - LY3462817 - SC
Administered SC
Drug - Placebo - IV
Administered IV
Drug - Placebo - SC
Administered SC
participant.views.study.view.additional
participant.views.study.view.scientific-title
A Multiple-Dose, Randomized, Placebo-Controlled, Study of LY3462817 in Patients With Psoriasis
common.study.values.clinical-trial-id
NCT04152382
participant.views.study.view.id
azpZ8d
